Loading clinical trials...
Loading clinical trials...
Positron Emission Tomography Study of alpha2-adrenergic Receptors With [11C]Yohimbine
The main purpose of this study is to model tissue specific kinetics of \[11C\]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of \[11C\]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).
Age
20 - 35 years
Sex
MALE
Healthy Volunteers
Yes
Service de Neurologie C - Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, GHE
Bron, France
Start Date
May 21, 2018
Primary Completion Date
July 21, 2018
Completion Date
January 21, 2019
Last Updated
September 12, 2025
16
ACTUAL participants
[11C]Yohimbine
DRUG
[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)
DRUG
Lead Sponsor
Hospices Civils de Lyon
NCT06780917
NCT06098612
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions